Cardiovascular Pathology
Volume 20, Issue 5 , Pages 315-321, September 2011

Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (Hurler syndrome) are activated valvular interstitial cells

  • Elizabeth Braunlin

      Affiliations

    • Department of Pediatrics, University of Minnesota Hospital/Fairview, Minneapolis, MN, USA
    • Corresponding Author InformationCorresponding author. Department of Pediatrics, University of Minnesota Hospital/Fairview, MMC 94, Minneapolis, MN 55455, USA. Tel.: +1 612 626 2755; fax: +1 612 626 2467.
    • ,
  • Jakub Tolar

      Affiliations

    • Department of Pediatrics, University of Minnesota Hospital/Fairview, Minneapolis, MN, USA
    • ,
  • Shannon Mackey-Bojack

      Affiliations

    • The Jesse E. Edwards Registry of Cardiovascular Disease, St. Paul, MN, USA
    • ,
  • Tiwanda Masinde

      Affiliations

    • Cellular and Molecular Pathology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
    • ,
  • William Krivit

      Affiliations

    • Department of Pediatrics, University of Minnesota Hospital/Fairview, Minneapolis, MN, USA
    • Deceased.
    • ,
  • Frederick J. Schoen

      Affiliations

    • Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Received 18 February 2010; received in revised form 6 May 2010; accepted 2 June 2010. published online 12 July 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by a grant from the Vikings Fund at the University of Minnesota Medical Foundation.

 Elizabeth Braunlin, MD, PhD receives speaker’s honoraria from Genzyme and Biomarin companies, both of which produce an enzyme treatment for MPS I.

 Jakub Tolar, MD, PhD receives speaker’s honoraria from Genzyme company.

PII: S1054-8807(10)00076-1

doi:10.1016/j.carpath.2010.06.004

Cardiovascular Pathology
Volume 20, Issue 5 , Pages 315-321, September 2011

Article Tools

* Image Usage & Resolution